|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8470 EUR | -1.97% |
|
-5.89% | -28.10% |
| 06-01 | NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation | CI |
| 06-01 | NFL Biosciences validates breakthrough in personalized medicine |  |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
Biological Products | ||||||
Biotechnology (Startups) | 39 | 22 | 200K | 46 | 188 | |
Total Assets | 3.69M | 2.4M | 3.97M | 3.61M | 3.66M | |
Interest Expense | -538 | -493 | -6.51K | -304 | -14.19K | |
Income Tax Expense | -141K | -418K | -366K | -635K | -540K | |
EBT | -1.12M | -2.9M | -4.11M | -2.72M | -3.86M | |
Operating Income | -902K | -3.08M | -4.23M | -2.79M | -3.87M | |
Net Income | -978K | -2.44M | -3.75M | -2.08M | -3.32M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
France | 39 | 22 | 200K | 46 | 188 | |
Total Assets | 3.69M | 2.4M | 3.97M | 3.61M | 3.66M | |
Interest Expense | -538 | -493 | -6.51K | -304 | -14.19K | |
Income Tax Expense | -141K | -418K | -366K | -635K | -540K | |
Net Income | -978K | -2.44M | -3.75M | -2.08M | -3.32M | |
EBT | -1.12M | -2.9M | -4.11M | -2.72M | -3.86M | |
Operating Income | -902K | -3.08M | -4.23M | -2.79M | -3.87M |
- Stock Market
- Stocks
- ALNFL Stock
- Financials NFL Biosciences
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
